Who’s the Next Buyout Target? 8×8, Inc. (EGHT), BroadSoft Inc (BSFT) and More

Page 1 of 2

This morning, when Oracle Corporation (NASDAQ:ORCL) announced its intention to buy digital communications specialist Acme Packet, Inc. (NASDAQ:APKT) , the move ignited a firestorm of speculation.

Is this the start of a buyout binge in the networked communications market, like the storage binge of 2009 or the data security party in 2010? Investors in the sector sure hope so. Oracle’s deal sparked huge gains in this sector, even as the broader market hit “pause” on its recent gains.

Speculation may be exciting, but does it make any sense?

8x8, Inc.Sonus Networks, Inc. (NASDAQ:SONS) gained 16% on Acme’s news, almost keeping pace with the 22% buyout premium on the deal target itself. The two companies are very direct competitors, focused above all else on the so-called session border controller devices that set up and manage Internet-based voice and video calls. So if Acme found a partner, shouldn’t someone come looking for Sonus soon enough?

Well, maybe. As a Sonus owner myself, I’ll admit that a buyout would be appreciated. The stock hasn’t done much for me over the last two years, due to the telecom industry’s seemingly endless reluctance to invest in truly next-generation technologies like voice over IP.

Sonus is also considerably cheaper than Acme, based on standard metrics like price-to-book or price-to-sales. But then, Acme is profitable today while Sonus isn’t. Any prospective buyer would have to stomach an extra-large dose of risk here. I’m not holding my breath for Sonus to find a buyer.

BroadSoft Inc (NASDAQ:BSFT) provides software-based alternatives to the hardware solutions wrangled by Sonus or Acme. This stock jumped 10% today, and got a favorable mention as analyst firm Needham poked and prodded the Acme deal’s implications.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!